News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
Content Sharing
<Research>M Stanley Cuts JD HEALTH's TP to HKD66, Lowers EPS Forecast
After factoring in JD HEALTH (06618.HK)'s 2025 results data, Morgan Stanley has raised its 2026-28 revenue forecasts for JD HEALTH (06618.HK) by 5%/ 6%/ 7% to reflect the conti...
Reset
Send
The window will close in 5 seconds
<Research>M Stanley Cuts JD HEALTH's TP to HKD66, Lowers EPS Forecast
Close
Recommend
10
Positive
9
Negative
6
 
 

After factoring in JD HEALTH (06618.HK)  +0.320 (+0.658%)    Short selling $77.28M; Ratio 154.143%   's 2025 results data, Morgan Stanley has raised its 2026-28 revenue forecasts for JD HEALTH (06618.HK)  +0.320 (+0.658%)    Short selling $77.28M; Ratio 154.143%   by 5%/ 6%/ 7% to reflect the continued growth momentum in online pharmaceutical sales.

In Morgan Stanley's estimate, JD HEALTH's 2026 revenue growth will rise by 18%, in which pharmaceutical sales, non-pharmaceutical sales, and service income will increase by 25%, 12%, and 19% YoY.

In terms of earnings, Morgan Stanley predicts JD HEALTH's 2026 adjusted operating profit to remain flat. It has cut the 2026-28 adjusted EPS forecasts by 4%/ 5%/ 6%.

Morgan Stanley's target price for JD HEALTH has fallen from HKD70 to HKD66.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

AASTOCKS Financial News

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.